📰 Project Orbis News
Page 7 - Project Orbis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Project Orbis. Real-time updates on events, politics, business and more.
August 8, 2022
AstraZeneca's Enhertu approved in the US for HER2-low metastatic breast cancer
August 6, 2022
LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo said Friday that the Food and Drug Administration approved Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients
August 6, 2022
FinancialContent fully hosted finance channel
August 6, 2022
NUBEQA now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall...
August 6, 2022
(RTTNews) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo said Friday that the Food and Drug Administration approved Enhertu (fam-trastuzumab deruxt...
August 5, 2022
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients...
August 1, 2022
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2022 Earnings Conference Call July 29, 2022 2:00 AM ETCompany ParticipantsHiroyuki Okuzawa - Head, Corporate Planning and Management...
July 26, 2022
Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class
July 25, 2022
Investegate announcements from AstraZeneca PLC, Enhertu granted Priority Review for HER2-low mBC